Company Description
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally.
The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure.
The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures.
In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators.
The company was founded in 1988 and is headquartered in Latham, New York.
| Country | United States |
| Founded | 1988 |
| IPO Date | May 27, 2004 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 748 |
| CEO | James Clemmer |
Contact Details
Address: 14 Plaza Drive Latham, New York 12110 United States | |
| Phone | 518 795 1400 |
| Website | angiodynamics.com |
Stock Details
| Ticker Symbol | ANGO |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001275187 |
| CUSIP Number | 03475V101 |
| ISIN Number | US03475V1017 |
| Employer ID | 11-3146460 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James C. Clemmer | Chief Executive Officer, President and Director |
| Stephen A. Trowbridge | Executive Vice President and Chief Financial Officer |
| Chad T. Campbell | Senior Vice President and GM of Global Vascular Access and Oncology Business Unit |
| Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality and Global Supply Chain |
| Laura Piccinini | Senior Vice President and GM of Endovascular Therapies and International |
| Saleem M. Cheeks | Vice President of Communications |
| Benjamin H. Davis | Senior Vice President of Business Development and Strategy |
| Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
| Kim L. Seabury | Senior Vice President of Information Technology |
| Juan Carlos Serna | Senior Vice President of Scientific and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 3, 2024 | 10-Q | Quarterly Report |
| Oct 3, 2024 | 8-K | Current Report |
| Sep 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 26, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 25, 2024 | 10-K | Annual Report |
| Jul 16, 2024 | 8-K | Current Report |
| Jul 16, 2024 | 8-K | Current Report |